hsa-mir-152: Hsa-mir-152 is a microRNA that has been associated with various diseases and conditions. It has been found to be altered in the early stage of Hepatitis C Virus (HCV) infection and is associated with a deterioration in liver function and increased severity of HCV [PMC10138470]. In gastric cancer cell lines, the expression of hsa-mir-152 was significantly downregulated [PMC8548500]. It has also been reported that hsa-mir-152 is repressed in endometrial cancer compared to normal tissue, suggesting its potential as a biomarker for endometrial cancer [PMC5453480]. In a study on colorectal adenocarcinoma patients, hsa-mir-152 was identified as an independent prognostic factor [PMC7047168]. Hsa-mir-152 has also been predicted to target TGFA in a network analysis, suggesting its potential role in regulating TGFA expression [PMC5663837]. Computational analysis identified hsa-mir-152 as one of the microRNAs predicted to regulate the expression of DNMT1 and DNMT3a/b [PMC4334912]. The expression levels of hsa-mir-152 have been found to be differentially expressed between drug-sensitive and drug-resistant tissues [PMC4706521]. Hsa-mir-152 has also been identified as one of the top miRNAs based on topological features in network analysis studies [PMC5453480][PMC7578500]. Overall, hsa-mir-152 is an important microRNA that plays a role in various diseases and conditions. Its altered expression levels have been associated with HCV infection, gastric cancer, endometrial cancer, colorectal adenocarcinoma, drug resistance, and other conditions. Further research is needed to fully understand its mechanisms and potential therapeutic implications.